← Edwards Lifesciences Corp EW
Market Price
$91.54
Market Cap
$53.29B
P/E Ratio
50.02
Revenue (FY 2025)
↑11.5% YoY
$6.07B
3-Yr CAGR: 4.1%
Net Income
↓-74.3% YoY
$1.07B
Net Margin: 17.7%
Free Cash Flow
↑360.5% YoY
$1.33B
FCF Yield: 2.51%
EPS (Diluted)
↓-73.7% YoY
$1.83
Basic: $1.84
Return on Equity
Efficiency
10.4%
ROA: 15.9%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (EW)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $2,963.7M | — | $2,166.3M | $569.5M | — | $0.87 | — | $704.4M | $528.3M | — |
| FY 2017 | $3,435.3M | +15.9% | $2,560.0M | $583.6M | +2.5% | $0.90 | +3.4% | $1,000.7M | $832.6M | +57.6% |
| FY 2018 | $3,722.8M | +8.4% | $2,783.4M | $722.2M | +23.7% | $1.13 | +25.2% | $926.8M | $688.1M | -17.4% |
| FY 2019 | $4,348.0M | +16.8% | $3,233.6M | $1,046.9M | +45.0% | $1.64 | +45.9% | $1,179.4M | $925.0M | +34.4% |
| FY 2020 | $4,386.3M | +0.9% | $3,305.7M | $823.4M | -21.3% | $1.30 | -20.9% | $1,054.3M | $647.3M | -30.0% |
| FY 2021 | $5,232.5M | +19.3% | $3,983.6M | $1,503.1M | +82.5% | $2.38 | +83.1% | $1,732.1M | $1,406.3M | +117.3% |
| FY 2022 | $5,382.4M | +2.9% | $4,302.0M | $1,521.9M | +1.3% | $2.44 | +2.5% | $1,218.2M | $973.6M | -30.8% |
| FY 2023 | $6,004.8M | +11.6% | $4,625.0M | $1,402.4M | -7.9% | $2.30 | -5.7% | $895.8M | $642.8M | -34.0% |
| FY 2024 | $5,439.5M | -9.4% | $4,322.0M | $4,174.6M | +197.7% | $6.97 | +203.0% | $542.3M | $289.9M | -54.9% |
| FY 2025 | $6,067.6M | +11.5% | $4,733.4M | $1,073.5M | -74.3% | $1.83 | -73.7% | $1,595.2M | $1,335.0M | +360.5% |
Valuation
Market Price
$91.54
Market Cap
$53.29B
Enterprise Value
$50.95B
P/E Ratio
50.02
P/B Ratio
5.10
FCF Yield
2.51%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
78.01%
Operating Margin
20.84%
Net Margin
17.69%
Return on Equity (ROE)
10.38%
Return on Assets (ROA)
15.93%
Asset Turnover
0.90x
Revenue 3-Yr CAGR
4.08%
Financial Health & Liquidity
Current Ratio
3.72
Cash Ratio
1.62
Debt / Equity
0.058
Debt / Assets
0.089
Cash & Equivalents
$2.94B
Total Debt
$598.30M
Book Value / Share
$17.95
Cash Flow Efficiency
Operating Cash Flow
$1.60B
Capital Expenditures (CapEx)
$260.20M
Free Cash Flow
$1.33B
OCF / Revenue
26.29%
FCF / Revenue
22.00%
FCF 3-Yr CAGR
11.10%
Per Share Metrics
EPS (Diluted)
$1.83
EPS (Basic)
$1.84
Dividends / Share
N/A
Book Value / Share
$17.95
EPS YoY Growth
-73.74%
Balance Sheet (FY 2025)
Total Assets
$6.74B
Total Liabilities
$1.81B
Stockholders' Equity
$10.34B
Current Assets
$6.74B
Current Liabilities
$1.81B